Evidence map›Paper›PMID 41293238›Full record

ArticleFrontiers in pharmacology2025

Luteolin induces apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia cell by regulating the PI3K/AKT signaling pathway.

Qin Ren, Xiaobing Li, Xiangmei Ye, Leiguang Feng

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Qin RenDepartment of Laboratory Diagnostics, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Xiaobing LiDepartment of Laboratory Diagnostics, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Xiangmei YeDepartment of Laboratory Diagnostics, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Leiguang FengDepartment of Laboratory Diagnostics, The First Affiliated Hospital of Harbin Medical University, Harbin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) represents the most prevalent genetic subtype of adult acute lymphoblastic leukemia (ALL). Despite the availability of targeted therapy regimens, patients with comorbidities and older patients have poor prognoses. They are prone to relapse, necessitating the urgent identification of new safe and effective treatment options. Luteolin (LUT), a natural flavonoid compound, has demonstrated significant anticancer activity. However, its mechanism of action in the context of Ph + ALL remains poorly understood. The objective of this study was to elucidate the potential mechanisms underlying the action of luteolin in Ph + ALL. Methods: Luteolin-related targets and Ph + ALL associated targets were collected from several public databases. The intersection of these targets was then analyzed for protein-protein interactions (PPI). Additionally, we performed functional and pathway enrichment analyses employing the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) methodologies. Core targets were selected from the PPI network, and some of these targets were further verified through cellular experiments. Results: A total of 568 luteolin targets and 1,063 Ph + ALL targets were identified, with 154 overlapping targets. The top ten targets with the highest degree values were selected as core targets, which include TP53, AKT1, ALB, TNF, JUN, IL6, EGFR, STAT3, CASP3, and BCL2. Based on GO and KEGG enrichment results, the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signaling pathway was further investigated. Cell experiments demonstrated that luteolin reduced the viability of SUP-B15 cells in a time- and concentration-dependent manner. Additionally, luteolin led to an increase in reactive oxygen species (ROS) accumulation, a decrease in mitochondrial membrane potential (MMP), and a reduction in ATP content in SUP-B15 cells. At the molecular level, luteolin significantly downregulated the protein expression of p-PI3K, p-AKT, p-STAT3 and BCL-2, while upregulating the protein expression of BAX, cleaved caspase-3, and cleaved caspase-9. Conclusion: Luteolin may exert anti-Ph + ALL effects through the PI3K/AKT signaling pathway, accompanied by the regulation of other targets such as STAT3, which provides a theoretical basis for the development and screening of novel anti-Ph + ALL therapies.

Indexed as

apoptosisluteolinnetwork pharmacologyPhiladelphia chromosome-positive acute lymphoblastic leukemiaPI3K/AKT signaling pathway

Identifiers

PMID41293238
PMCPMC12641114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.